Prediction of Quality Markers (Q-Markers) for the Mongolian Medicine Naru-3 Based on Chemical Composition, Pharmacological Effects, and Network Pharmacology

Ying En, Liang Xu, Jiaqi Yu

Show Less

¹ Mongolian Medicine College, Inner Mongolia University for Nationalities, Tongliao 028000, Inner Mongolia, China,

² Chemistry and Materials Science College, Inner Mongolia University for Nationalities, Tongliao 028000, Inner Mongolia, China,

JCNR 2025 , 9(1), 1–10; https://doi.org/10.26689/jcnr.v9i1.9387

© 2025 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Abstract

Naru Sanwei Pill, also known as Naru-3, a Mongolian medicine originating from Zhigao Pharmacopoeia, is a classic prescription used in the treatment of rheumatism. It is composed of Terminalia chebula, processed Aconitum kusnezoffii Reichb., and Piper longum, and is known for its effects in eliminating “mucus,” relieving pain, and reducing swelling, with significant efficacy in treating joint effusion and lumbar pain. In recent years, researchers have summarized its chemical components and pharmacological effects, and employed network pharmacology methods based on the core theory of Traditional Chinese Medicine quality markers (Q-Markers) to analyze and predict its markers. The results identified potential Q-Markers for Naru-3, providing a scientific basis for quality control and further research.

References

Editorial Committee of Mongolian Medicine, 1992, Encyclopedia of Chinese Medicine: Mongolian Medicine. Shanghai Science and Technology Press, Shanghai, 249–250.

Chinese Pharmacopoeia Commission, 1998, Ministry of Health Drug Standards of the People’s Republic of China: Mongolian Medicine. Inner Mongolia Science and Technology Press, Chifeng, 95.

Liu C, Chen S, Xiao X, et al., 2016, Quality Markers (Q-Markers) of Traditional Chinese Medicine: A New Concept for Quality Control of Chinese Medicine Products. China Journal of Chinese Materia Medica, 47(9): 1443–1457.

Liu C, 2021, Five-Year Review on the Research and Development of Quality Markers (Q-Markers) in Traditional Chinese Medicine. China Journal of Chinese Materia Medica, 52(9): 2511–2518.

Zhang A, Qigeqin, Han Z, 2024, Origin Tracing and Modern Research Progress of Mongolian Medicine Naru Sanwei Pills. Chinese Journal of Ethnomedicine and Ethnopharmacy, 30(1): 51–56.

Li Q, Sun S, Wang M, et al., 2018, Chemical Constituents and Analgesic Activity of Aconitum kusnezoffii Reichb. Journal of Chinese Pharmaceutical Sciences, 27(12): 855–863.

Peng S, 2014, Study on Alkaloids in Aconitum kusnezoffii, dissertation, Jilin University.

Zhi M, Gu X, Han S, et al., 2020, Chemical Composition Analysis of Aconitum kusnezoffii and Its Different Processed Products Using UPLC-Orbitrap-MS. China Journal of Chinese Materia Medica, 45(5): 1082–1089.

Zhang H, Zhang H, Zhang C, et al., 2023, Identification of Chemical Components in Mongolian Medicine Piper longum Using UPLC-Q-Exactive-MS Technology. Central South Pharmacy, 21(2): 442–448.

Liu J, Zhao T, Zhang H, et al., 2025, Chemical Constituents and Antitumor Activity of Piper longum. Chinese Traditional Patent Medicine, Published online ahead of print. http://kns.cnki.net/kcms/detail/31.1368.R.20241218.1538.002.html

Zhou K, Jian P, Liang W, et al., 2020, Chemical Composition Analysis of Tibetan Medicines Terminalia chebula and Terminalia bellirica Based on UPLC-Q-Exactive Orbitrap-MS. Journal of Mass Spectrometry, 41(3): 254–267.

Wang W, Zhang Q, Yang W, et al., 2024, Determination of Chebulinic Acid and Chebulagic Acid in Terminalia chebula by HPLC. Chemical Analysis and Meterage, 33(1): 22–26 + 64.

Yang X, Tang R, 2012, Study on the Chemical Components of Terminalia chebula. Journal of Xichang College (Natural Science Edition), 26(2): 65–66.

Li J, Zhang Q, Wang Y, et al., 2024, Quality Evaluation of Mongolian Medicine Naru Sanwei Pills Based on HPLC-MS/MS and Chemometric Analysis. Chinese Journal of Hospital Pharmacy, 44(11): 1277–1284.

Cao R, Yu Y, Gu Y, et al., 2018, HPLC-DAD Fingerprint Study of Mongolian Medicine Naru-3. China Journal of Traditional Chinese Medicine and Pharmacy, 29(8): 1877–1881.

Yue N, Cherimu, Li H, et al., 2024, Effect of Mongolian Medicine Naru Sanwei Pills Combined with Pregabalin and Nerve Block on Neuropathic Pain. Journal of Clinical Anesthesiology, 40(10): 1068–1072.

Zong Y, Cao R, Li Y, et al., 2024, Intervention of Mongolian Medicine Naru-3 on Neuroinflammation in the “Maintenance Phase” of Neuropathic Pain by Inhibiting Astrocyte Activation. China Journal of Chinese Materia Medica, 49(11): 2991–3001.

Bai M, Tu Y, Bagena, et al., 2010, Therapeutic Effects and Mechanisms of Mongolian Medicine Naru Sanwei Pills on Adjuvant Arthritis. Chinese Traditional Patent Medicine, 32(9): 1488–1491.

Zhao H, Zhang X, Duan S, et al., 2024, Protective Effects of Naru-3 on Collagen-Induced Arthritis in Rats. Chinese Traditional Patent Medicine, 46(6): 1842–1849.

E’nirile, 2024, Study on the Mechanism of Mongolian Medicine Naru Sanwei Pills in Treating Rheumatoid Arthritis Based on Proteomics, dissertation, Inner Mongolia University for Nationalities.

Liu XR, Li SF, Mei WY, et al., 2024, Isorhamnetin Downregulates MMP2 and MMP9 to Inhibit Development of Rheumatoid Arthritis through SRC/ERK/CREB Pathway. Chin J Integr Med, 30(4): 299–310. https://doi.org/10.1007/s11655-023-3753-6

Diao J, Xu H, Ma X, et al., 2024, Inhibitory Effect of Gallic Acid on LPS-Induced Inflammatory Response in Human THP-1 Macrophages. Chinese Journal of Comparative Medicine, 34(4): 41–53.

Yang G, Guo R, Xie J, et al., 2025, The Mechanism of Piperine Alleviating LPS/Nigericin-Induced Inflammation in iB-MDM. Modern Food Science and Technology, Published online ahead of print. https://doi.org/10.13982/j.mfst.1673-9078.2025.11.1168

Calderwood SK, Gong J, 2016, Heat Shock Proteins Promote Cancer: It’s a Protection Racket. Trends Biochem Sci, 41(4): 311–323. https://doi.org/10.1016/j.tibs.2016.01.003

Zheng D, Bao L, Bian J, 2024, Progress in Research on Anti-Tumor Drugs Targeting PIK3CA Mutations. Chinese Journal of Cancer Biotherapy, 31(2): 175–182.

Li H, Xing T, Wei G, et al., 2024, Research Progress on the Role of the PI3K/Akt Signaling Pathway in Rheumatoid Arthritis. Chinese Journal of Osteoporosis, 30(7): 1060–1066.

Wang H, Guo M, Wei H, et al., 2023, Targeting p53 Pathways: Mechanisms, Structures, and Advances in Therapy. Signal Transduct Target Ther, 8(1): 92. https://doi.org/10.1038/s41392-023-01347-1

Liu M, Zhang M, Xie M, 2018, Molecular Mechanisms of Anti-Inflammatory Effects of Adenosine Monophosphate-Activated Protein Kinase. Acta Physiologica Sinica, 70(3): 329–334.

Previous article in this issue

Next article in this issue